Patient characteristics of the study cohort
| Parameters . | All patients . | CAR-T naive . | CAR-T exposed . | P value . |
|---|---|---|---|---|
| Patient number, % | 70 (100%) | 20 (29%) | 50 (71%) | — |
| Age at lymphoma diagnosis, (R), y | 62 (23-94) | 65 (23-94) | 62 (27-77) | .668 |
| Gender, n (%) | ||||
| Male | 41 (59%) | 12 (60%) | 29 (58%) | 1.000 |
| Female | 29 (41%) | 8 (40%) | 21 (42%) | — |
| Lymphoma types | ||||
| DLBCL de novo, n (%) | 40 (57%) | 12 (60%) | 28 (56%) | .796 |
| GCB | 13 (19%) | 1 (5%) | 12 (24%) | .091 |
| Non-GCB | 16 (23%) | 7 (35%) | 9 (18%) | .206 |
| NOS | 11 (16%) | 4 (20%) | 7 (14%) | .717 |
| DLBCL transformed from lg-NHL, n (%) | 18 (26%) | 5 (25%) | 13 (26%) | 1.000 |
| HGBL with MYC and BCL2/BCL6 rearrangement, n (%) | 9 (13%) | 2 (10%) | 7 (14%) | .707 |
| HGBL NOS, n (%) | 2 (3%) | 1 (5%) | 1 (2%) | — |
| TCRLBCL, n (%) | 1 (1%) | — | 1 (2%) | — |
| Median time from dx to glo, mo (R) | 20 (7-295) | 14 (6-47) | 30 (9-296) | .003 |
| Therapies before glo | ||||
| Median therapy lines prior glo, n (R) | 4 (2-14) | 4 (2-13) | 4.5 (2-14) | .042 |
| Anti-CD20/anthracycline-based reg., n (%) | 67 (96%) | 18 (90%) | 49 (98%) | .194 |
| Platinum-based salvage reg., n (%) | 63 (90%) | 16 (80%) | 47 (94%) | .097 |
| Benda/ritux ± polatuz. ved., n (%) | 49 (70%) | 16 (80%) | 33 (66%) | .387 |
| Benda w/in last 6 mo before glo, n (%) | 24 (34%) | 11 (55%) | 13 (26%) | .072 |
| Tafasitamab/lenalidomide, n (%) | 24 (34%) | 9 (45%) | 15 (30%) | .272 |
| PD-1 inhibitor, n (%) | 6 (9%) | 1 (5%) | 5 (10%) | .666 |
| Ibrutinib, n (%) | 4 (6%) | 1 (5%) | 3 (6%) | 1.000 |
| Prior autologous SCT, n (%) | 22 (31%) | 4 (20%) | 18 (36%) | .259 |
| Prior allogeneic SCT, n (%) | 7 (10%) | 2 (10%) | 5 (10%) | 1.000 |
| Bulky disease (>7.5 cm) before glo, avail. for 69/70 pts | 22 (32%) | 9 (45%) | 13 (27%) | .161 |
| Extranodal lesions before glo, avail. for 64/70 pts | 23 (36%) | 7 (37%) | 16 (36%) | .161 |
| Median LDH U/L before glo, n (R) | 400 (157-1799) | 468 (157-1644) | 388 (172-1799) | .406 |
| IPI before glo, avail. for 63/70 pts | ||||
| IPI low (0-1) | 8 (13%) | 2 (11%) | 6 (14%) | 1.000 |
| IPI low-int. (2) | 9 (14%) | 4 (21%) | 5 (11%) | .434 |
| IPI high-int. (3) | 26 (41%) | 8 (42%) | 18 (41%) | 1.000 |
| IPI high (4-5) | 20 (32%) | 5 (26%) | 15 (34%) | .769 |
| Dx confirming bx before glo, n (%) | 38 (54%) | 5 (25%) | 33 (66%) | .003 |
| CD20 positivity by IHC before glo | ||||
| CD20+ lymphoma | 35/38 (92%) | 4/5 (80%) | 31/33 (94%) | — |
| CD20– lymphoma | 3 (8%) | 1/5 (20%) | 2/31 (6%) | — |
| Refractory to last tx, % (avail. for 69/70 pts) | 49 (71%) | 19 (100%) | 30 (60%) | .0002 |
| Parameters . | All patients . | CAR-T naive . | CAR-T exposed . | P value . |
|---|---|---|---|---|
| Patient number, % | 70 (100%) | 20 (29%) | 50 (71%) | — |
| Age at lymphoma diagnosis, (R), y | 62 (23-94) | 65 (23-94) | 62 (27-77) | .668 |
| Gender, n (%) | ||||
| Male | 41 (59%) | 12 (60%) | 29 (58%) | 1.000 |
| Female | 29 (41%) | 8 (40%) | 21 (42%) | — |
| Lymphoma types | ||||
| DLBCL de novo, n (%) | 40 (57%) | 12 (60%) | 28 (56%) | .796 |
| GCB | 13 (19%) | 1 (5%) | 12 (24%) | .091 |
| Non-GCB | 16 (23%) | 7 (35%) | 9 (18%) | .206 |
| NOS | 11 (16%) | 4 (20%) | 7 (14%) | .717 |
| DLBCL transformed from lg-NHL, n (%) | 18 (26%) | 5 (25%) | 13 (26%) | 1.000 |
| HGBL with MYC and BCL2/BCL6 rearrangement, n (%) | 9 (13%) | 2 (10%) | 7 (14%) | .707 |
| HGBL NOS, n (%) | 2 (3%) | 1 (5%) | 1 (2%) | — |
| TCRLBCL, n (%) | 1 (1%) | — | 1 (2%) | — |
| Median time from dx to glo, mo (R) | 20 (7-295) | 14 (6-47) | 30 (9-296) | .003 |
| Therapies before glo | ||||
| Median therapy lines prior glo, n (R) | 4 (2-14) | 4 (2-13) | 4.5 (2-14) | .042 |
| Anti-CD20/anthracycline-based reg., n (%) | 67 (96%) | 18 (90%) | 49 (98%) | .194 |
| Platinum-based salvage reg., n (%) | 63 (90%) | 16 (80%) | 47 (94%) | .097 |
| Benda/ritux ± polatuz. ved., n (%) | 49 (70%) | 16 (80%) | 33 (66%) | .387 |
| Benda w/in last 6 mo before glo, n (%) | 24 (34%) | 11 (55%) | 13 (26%) | .072 |
| Tafasitamab/lenalidomide, n (%) | 24 (34%) | 9 (45%) | 15 (30%) | .272 |
| PD-1 inhibitor, n (%) | 6 (9%) | 1 (5%) | 5 (10%) | .666 |
| Ibrutinib, n (%) | 4 (6%) | 1 (5%) | 3 (6%) | 1.000 |
| Prior autologous SCT, n (%) | 22 (31%) | 4 (20%) | 18 (36%) | .259 |
| Prior allogeneic SCT, n (%) | 7 (10%) | 2 (10%) | 5 (10%) | 1.000 |
| Bulky disease (>7.5 cm) before glo, avail. for 69/70 pts | 22 (32%) | 9 (45%) | 13 (27%) | .161 |
| Extranodal lesions before glo, avail. for 64/70 pts | 23 (36%) | 7 (37%) | 16 (36%) | .161 |
| Median LDH U/L before glo, n (R) | 400 (157-1799) | 468 (157-1644) | 388 (172-1799) | .406 |
| IPI before glo, avail. for 63/70 pts | ||||
| IPI low (0-1) | 8 (13%) | 2 (11%) | 6 (14%) | 1.000 |
| IPI low-int. (2) | 9 (14%) | 4 (21%) | 5 (11%) | .434 |
| IPI high-int. (3) | 26 (41%) | 8 (42%) | 18 (41%) | 1.000 |
| IPI high (4-5) | 20 (32%) | 5 (26%) | 15 (34%) | .769 |
| Dx confirming bx before glo, n (%) | 38 (54%) | 5 (25%) | 33 (66%) | .003 |
| CD20 positivity by IHC before glo | ||||
| CD20+ lymphoma | 35/38 (92%) | 4/5 (80%) | 31/33 (94%) | — |
| CD20– lymphoma | 3 (8%) | 1/5 (20%) | 2/31 (6%) | — |
| Refractory to last tx, % (avail. for 69/70 pts) | 49 (71%) | 19 (100%) | 30 (60%) | .0002 |
The P values are obtained using Fisher's exact test for categorical data and Mann-Whitney U test for metric data. Significant P values are set in bold.
avail, available; Benda, bendamustine; BCL2/BCL6, B-cell lymphoma 2/B-cell lymphoma 6; bx, biopsy; dx, diagnosis; dz, disease; GCB, germinal center B-cell–like type; glo, glofitamab; IHC, immunohistochemistry; int., intermediate; IPI, International Prognostic Index; lg-NHL, low-grade Non-Hodgkin lymphoma; MYC, myelocytomatosis oncogene; polatuz. ved, polatuzumab vedotin; PD-1, programmed death protein-1; pts, patients; R, range; reg., regimen; ritux, rituximab; TCRLBCL, T-cell/histiocyte-rich LBCL; tx, therapy.